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and hundreds ofvariants in specific genes
involved in environmental exposures, deci-
phering the data is where things get tricky.
"As we layer on hundreds and thousands of
variations, I suspect it will be a very diffi-
cult task for the epidemiologists, statisti-
cians, geneticists, and biochemists who try
to explain exactlywhat's going on at a bio-
logical level," Bell said. "In reality, there
may be many alternative pathways at each
step in the exposure-disease path and we
really don't know how to model or even
thinkabout these systems at this point."
Understanding the interaction between
genes and environment enables scientists to
have greater accuracy and precision in the
measurement and detection ofboth genetic
and environmental effects, said Ottman.
She offered a series of epidemiological
models of interaction at the meeting and
remains confident that as more genes that
affect disease risk continue to be identified,
testing of interaction models will become
more feasible; the next step is disease pre-
vention.
Despite exciting emerging perspectives
on exposure, interactions, and risk, for
now, said Schonwalder, "we don't know a
lot, but one thingwe can sayforsure is that
we're not getting it right. We're spending
billions ofdollars to control chemicals and
we don't know which ones are really haz-
ardous and which are not. We're either
overcontrolling, which means we're spend-
ing a lot of money in the economy that
doesn't need to be spent, or we're under-
controlling, in which case we're causing a
lot of human suffering and disease and
we're spending an awful lotonhealth care."
Finally, Schonwalder said, "The returns on
investment in research toward understand-
ingdisease cause and effect can behuge."
understanding howAAV enters cells, scien-
tists will have more information for decid-
ing how and when to use the virus for
effective human gene therapy.
Gene therapy works by using a geneti-
cally altered vector to convey replacement
genes to diseased cells. AAV is commonly
used for this purpose because it can infect
several different kinds of cells (unlike, for
example, the AIDS virus, which attacks
only a specific type ofwhite blood cell). It
is also nonpathogenic, so practitioners
don't have to worry about the vector caus-
ing adverse health effects in their patients.
AAV is currently used in gene therapies for
cystic fibrosis, Parkinson's disease, and
hemophilia, amongother conditions.
Integrins occur in various combinations
of 1 of 16 different alpha subunits and 1 of
8 different beta subunits. Understanding
the role that the aVO5 integrin plays in
AAV uptake will allow researchers flexibili-
ty in exploiting its properties, depending
on the needs of the disease being treated.
For instance, they could upregulate the
receptor (or increase its numbers on the cell
surface) to enhance uptake.
The UNC research team built upon
earlier studies that showed that adenovirus
interacts with axV integrins to facilitate
internalization ofthevirus. Adenovirus uses
two different receptors to mediate viral
infection. The first receptor attaches wan-
dering viruses to the cell surface, and the
second receptor, the aVfi5 integrin, actual-
ly "pulls" the virus inside the cell. Because
AAV coevolved with adenovirus, the UNC
team thought that the two viruses might
share one of the same receptors. In fact,
they found that they share the secondary
receptor but not thefirst.
The team compared hamster cell lines
that either lacked aVP5 or specifically
A New Window on
a Molecular
Doorway
Research published in the
January 1999 issue ofNature
Medicine may help scientists
make a good thing-gene
therapy-even better.
Investigators at the Uni-
versity of North Carolina at
Chapel Hill (UNC) have
found that the presence of
aVj5 integrins (a certain
type of receptor protein) on
cell surfaces makes it easier
for those cells to be infected
with adeno-associated virus
(AAV), a commonly used
gene therapyvector, or deliv-
ery mechanism. By better
attachment o internalization
AMV
aV5Sintegrin
11 / cell
attachmnt scmm
recptr recptr
The key to infection? Identification of the aVI5 integrin as a secondary
receptor for adeno-associated virus (AAV) offers evidence of how viruses
infect cells, and may provide gristfor new genetherapies.
expressed aVfi5. The cells were exposed to
recombinant forms of adenovirus and
AAV. They found that infection rates of
the aV,B5-positive cells were 260% higher
for AAV (and 320% higher for adenovirus)
than in the cells that lacked the aV,5 inte-
grin. To determine whether, and to what
extent, aVP5 speeds AAV entry into a cell,
the scientists applied a strain of the virus
tagged with fluorescent dye to the two cell
lines. The aV[5-positive line was found to
internalize the virus at a much faster rate
(within 10 minutes) than the aVP5-defi-
cient line (which took up to 60 minutes).
Candace M. Summerford, a graduate stu-
dent at the Gene Therapy Center at UNC
who led the study, says, "We're lookingat a
phenomenon that facilitates viral entry but
isn't absolutely necessary." However, she
continues, "How fast the virus can get into
the cell may define the odds of infection."
Summerford's team is currently investigat-
ing the use ofAAV as a vector for anti-
cancerstrategies.
According to R. Jude Samulski, direc-
tor ofthe Gene Therapy Center, AAV is a
defective parvovirus, meaning it is unable
to complete its life cycle on its own. It
needs the assistance ofa "helper" cell such
as adenovirus or, as was more recently dis-
covered, herpesvirus. Because AAV can
coexist with at least two different helper
viruses, it may have multiple avenues of
entry into a cell; that is, it may have access
to the sum ofthe different cells targeted by
its helper cells. Identification of the viral
receptors for AAV has helped researchers
understand the broad access to cells ofthis
virus. It is this "tropism" of AAV that
makes the virus a good choice for a gene
therapy vector, because it can be used to
transport replacement proteins into several
different environments. making it a sort of
all-terrain vehicle ofgene therapy.
E A better understanding of how
ci AAV enters cells may also help scien-
C. tists understand the more pathogenic
to strains ofparvovirus, such as the B19
E strain, which causes erythema infectio-
sum ("fifth disease") in humans. This
disease is symptomized by a rash, low-
grade fever, fatigue, joint pain, and
swelling. B19 infection can be danger-
ous for patients with blood disorders
such as sickle cell anemia and hemo-
philia. In pregnant mothers, infection
with the B19 strain can result in spon-
taneous abortion.
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